Company Profile: Plakous Therapeutics

http://www.plakoustherapeutics.com
Sub-sector: Biotech and Pharmaceutical
Year Founded: 2016
Life Science Location: Main Stage & Innovation Room 

COMPANY PROFILE
Plakous is advancing regenerative healing by manufacturing biotherapeutics from the post-delivery human placenta. We will establish a safe and effective therapeutic platform that promotes and sustains healing using the placental cytokines and growth factors that orchestrate fetal development. The initial clinical targets for Plakous’ lead product, Protego-PD™, are preventing necrotizing enterocolitis and treating of osteoarthritis.

FOUNDERS/MANAGEMENT TEAM
Roger Nolan, CEO
Scott Washburn, CMO
Seth Tomblyn, CSO

KEY MILESTONES TO DATE

  • Accolades: Presented at 2018 CED Life Science Conference
  • Presented results from osteoarthritis study at 2 national orthopedic conferences and a military medicine meeting
  • Received a non-binding designation of a 351 Biologic from the FDA for Protego-PD™
  • Completed in vitro proof-of-principle studies for NEC, OA, nerve regeneration, and wound healing
  • Generated proof-of-concept data that Protego-PD halts the progression of PTOA in a severe rodent model of the disease
  • Generated proof-of-concept data that Protego-PD decreases the incidence of NEC in a pre-mature piglet model of NEC
  • Funding: $725,000-Converible Debt

POWERED BY
CED;Innovation Quarter;NC Biotechnology Center;SBTDC

CONTACT
Seth Tomblyn
stomblyn@plakoustherapeutics.com
Winston Salem, NC